These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31131594)

  • 1. Fosfomycin in antimicrobial stewardship programs.
    Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosfomycin in the pediatric setting: Evidence and potential indications.
    Baquero-Artigao F; Del Rosal Rabes T
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):55-61. PubMed ID: 31131593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study.
    Davido B; Bouchand F; Dinh A; Perronne C; Villart M; Senard O; Salomon J
    Int J Antimicrob Agents; 2017 Aug; 50(2):142-147. PubMed ID: 28694232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon.
    Ballouz T; Zeenny RM; Haddad N; Rizk N; Kanj SS
    J Infect Dev Ctries; 2021 Sep; 15(9):1308-1313. PubMed ID: 34669601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.
    Falagas ME; Roussos N; Gkegkes ID; Rafailidis PI; Karageorgopoulos DE
    Expert Opin Investig Drugs; 2009 Jul; 18(7):921-44. PubMed ID: 19548851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fosfomycin].
    Gobernado M
    Rev Esp Quimioter; 2003 Mar; 16(1):15-40. PubMed ID: 12750755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.
    Vardakas KZ; Legakis NJ; Triarides N; Falagas ME
    Int J Antimicrob Agents; 2016 Apr; 47(4):269-85. PubMed ID: 27013000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for resistant Gram-positive infections--a review.
    Strahilevitz J; Rubinstein E
    Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New microbiological aspects of fosfomycin.
    Díez-Aguilar M; Cantón R
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):8-18. PubMed ID: 31131587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant bacteria in hospitalized children: a 5-year multicenter study.
    Raymond J; Nordmann P; Doit C; Vu Thien H; Guibert M; Ferroni A; Aujard Y
    Pediatrics; 2007 Apr; 119(4):e798-803. PubMed ID: 17403822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of antimicrobial stewardship program on antimicrobial usage and detection rate of multidrug-resistant gram-negative bacteria].
    Xu YL; Hu LM; Xie ZZ; Dong YW; Dong L
    Zhonghua Er Ke Za Zhi; 2019 Jul; 57(7):553-558. PubMed ID: 31269557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.